SEC Company Response from Sonoma Pharmaceuticals, Inc. (SNOA) (CIK 0001367083) (SNOA) — Nov 29, 2011
Sonoma Pharmaceuticals, Inc. (SNOA) (CIK 0001367083)
Date: Nov. 29, 2011 · CIK: 0001367083 · Accession: 0001144204-11-067469
AI Filing Summary & Sentiment
Reasoning
Referenced dates: November 1, 2011
Letter
United States Securities and Exchange Commission Division of Corporation Finance Oculus Innovative Sciences, Inc. Registration Statement on Form S-3 Filed October 21, 2011 File No. 331-177462
Dear Mr. Mumford and Ms. Ravitz:
I am securities counsel for Oculus Innovative Sciences, Inc. (the “Company”). Set forth below is the Company’s response to comments received from the staff of the Securities and Exchange Commission (the “Staff”) in their letter dated November 1, 2011. The numbering of the response corresponds to the numbering of the comment in the letter from the Staff.
Exhibit 5.1
Comment 1:
We note that you intend to file your 5.1 opinion of counsel exhibit by a pre-effective amendment to this registration statement. Please allow sufficient time for us to conduct a substantive review of counsel’s opinion and resolve applicable comments, if any, prior to requesting effectiveness of this registration statement.
Response 1:
The Company will comply with this comment.
Exhibit 10.58
Comment 2:
Please ensure that your pending application for confidential treatment is granted prior to requesting acceleration of the effective date of this registration statement. Please see Section III.B.2 of Staff Legal Bulletin No. 1.
Response 2:
The Company will comply with this comment.
If you have further questions or comments, please feel free to contact me. I am happy to cooperate in any way I can.
Regards,
/s/ Amy M. Trombly, Esq.
Show Raw Text
CORRESP
1
filename1.htm
Unassociated Document
November 29, 2011
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attn:
Jay Mumford
Amanda Ravitz, Assistant Director
Re:
Oculus Innovative Sciences, Inc.
Registration Statement on Form S-3
Filed October 21, 2011
File No. 331-177462
Dear Mr. Mumford and Ms. Ravitz:
I am securities counsel for Oculus Innovative Sciences, Inc. (the “Company”). Set forth below is the Company’s response to comments received from the staff of the Securities and Exchange Commission (the “Staff”) in their letter dated November 1, 2011. The numbering of the response corresponds to the numbering of the comment in the letter from the Staff.
Exhibit 5.1
Comment 1:
We note that you intend to file your 5.1 opinion of counsel exhibit by a pre-effective amendment to this registration statement. Please allow sufficient time for us to conduct a substantive review of counsel’s opinion and resolve applicable comments, if any, prior to requesting effectiveness of this registration statement.
Response 1:
The Company will comply with this comment.
Exhibit 10.58
Comment 2:
Please ensure that your pending application for confidential treatment is granted prior to requesting acceleration of the effective date of this registration statement. Please see Section III.B.2 of Staff Legal Bulletin No. 1.
Response 2:
The Company will comply with this comment.
If you have further questions or comments, please feel free to contact me. I am happy to cooperate in any way I can.
Regards,
/s/ Amy M. Trombly, Esq.
Amy M. Trombly, Esq.